Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mao Okada

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Journal of Gastroenterology and Hepatology|April 25, 2019
Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarateShun Kaneko, Masayuki Kurosaki, Nobuharu Tamaki, et al.
Diseases (Basel, Switzerland)|August 28, 2024
Study Protocol for a Prospective Self-Controlled Trial on Success in Meeting Comprehensive Genomic Profiling Analysis Criteria for Specimens Obtained by Endoscopic Ultrasound-Guided Tissue Acquisition Using a 19G Needle from Primary and Metastatic Lesions in Pancreatic Cancer with Metastatic Lesions: The PRIMATE StudyKotaro Takeshita, Susumu Hijioka, Yoshikuni Nagashio, et al.
Journal of Medical Virology|January 30, 2020
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis BNobuharu Tamaki, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 13, 2018
Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infectionYutaka Yasui, Tokiya Abe, Masayuki Kurosaki, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|June 10, 2020
Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovirNobuharu Tamaki, Masayuki Kurosaki, Sakura Kirino, et al.
Cancers|August 30, 2019
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular CarcinomaHitomi Takada, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Plos One|April 21, 2020
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinomaSakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Japanese Journal of Clinical Oncology|March 7, 2025
Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113Mao Okada, Eiichiro Suzuki, Chigusa Morizane, et al.
Journal of Gastroenterology and Hepatology|January 25, 2020
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analogSakura Kirino, Nobuharu Tamaki, Shun Kaneko, et al.
Cancers|October 12, 2019
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World PracticeWan Wang, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Journal of Gastroenterology and Hepatology|April 25, 2019
Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarateShun Kaneko, Masayuki Kurosaki, Nobuharu Tamaki, et al.
Diseases (Basel, Switzerland)|August 28, 2024
Study Protocol for a Prospective Self-Controlled Trial on Success in Meeting Comprehensive Genomic Profiling Analysis Criteria for Specimens Obtained by Endoscopic Ultrasound-Guided Tissue Acquisition Using a 19G Needle from Primary and Metastatic Lesions in Pancreatic Cancer with Metastatic Lesions: The PRIMATE StudyKotaro Takeshita, Susumu Hijioka, Yoshikuni Nagashio, et al.
Journal of Medical Virology|January 30, 2020
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis BNobuharu Tamaki, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 13, 2018
Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infectionYutaka Yasui, Tokiya Abe, Masayuki Kurosaki, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|June 10, 2020
Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovirNobuharu Tamaki, Masayuki Kurosaki, Sakura Kirino, et al.
Cancers|August 30, 2019
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular CarcinomaHitomi Takada, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Plos One|April 21, 2020
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinomaSakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Japanese Journal of Clinical Oncology|March 7, 2025
Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113Mao Okada, Eiichiro Suzuki, Chigusa Morizane, et al.
Journal of Gastroenterology and Hepatology|January 25, 2020
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analogSakura Kirino, Nobuharu Tamaki, Shun Kaneko, et al.
Cancers|October 12, 2019
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World PracticeWan Wang, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Pageof 5